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Abstract Article Info 
Introduction: Nasopharyngeal carcinoma (NPC) has a high incidence rate in southern China and Southeast Asia 
and a high rate of metastasis in head and neck cancer. NPC is a squamous cell carcinoma that grows from the 
surface of the lateral wall of the nasopharynx. E-cadherin is known as a tumor suppressor protein and the loss 
of this expression in tumor cells is related to epithelial-mesenchymal transition that occurs during tumor 
development and metastasis. 
Objective: To determine the relationship between E-cadherin expression and clinical stage in patients with 
nasopharyngeal carcinoma. 
Methods: An analytical study with a cross-sectional study design, the number of samples was 30 patients with 
NPC who underwent immunohistochemical examination on KNF paraffin block.  
Result: Overexpression of E-cadherin was found in T1 and T2 of 15 subjects (100%). The overexpression of E-
cadherin was found in lymph node N2 and N3 of 19 subjects (95%). The overexpression of E-cadherin was 
found in the histopathological type of Non-Keratinizing Squamous Cell Carcinoma of 24 subjects (96%). The 
overexpression of E-cadherin was found at an advanced stage of 26 subjects (100%). 
Conclusion: No significant association was found between E-cadherin expression and tumor size (p=1.000), 
lymph node metastasis (p=1.000), histopathological type (p=1.000) and tumor stage (p=0.133). 
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Nasopharyngeal carcinoma (NPC) has a high incidence rate in southern 
China and Southeast Asia and a high rate of metastasis in head and neck 
cancer [1]. The close relationship between Epstein-Barr virus infection and 
NPC shows that NPC grows as cancer associated with inflammation [1]. 
NPC is a squamous cell carcinoma that grows from the surface of the lateral 
wall of the nasopharynx [2]. In some countries in the world including the United 
States of America, the NPC is relatively rare and has an incidence of <1 case per 
100.000 population every year. Among Asian populations, especially in South 
China, the NPC is in the rank of 11 malignancies that often occur with an average 
incidence rate almost 25 cases per 100.000 population [3]. 
NPC is one of the most common cancers in South China and 
Southeast Asia [4]. According to the WHO (World Health Organization), 
the most common type of histology is undifferentiated carcinoma [5]. A 
high incidence occurs in several regions of South China, especially in 
Guangzhou province, with an incidence of around 30-80 per 100.000 
population per year [6] causing serious health problems [4]. Medium 
incidents occurred in Southeast Asia including Singapore (15 per 
100.000), Malaysia (9.7 per 100.000), Vietnam (7.5 per 100.000), Taiwan 
(7 per 100.000) and the Philippines (6.4 per 100.000). This tendency also 
applies in Africa, including Kenya (5.4 per 100.000) and Algeria, 
Morocco, and Tunisia (5.1 per 100.000) [7]. 
NPC with more than 13,000 new cases annually is one of the most 
common types of malignancy in Indonesia, especially in men and is 
associated with a high mortality rate [8]. The incidence of NPC in Indonesia 
is estimated at 6.2 per 100.000 or around 12.000 new cases occur each year [7]. 
E-cadherin is known as tumor suppressor protein and the loss of this 
expression in tumor cells is related to epithelial-mesenchymal transition 
(EMT) that occurs during tumor development and metastasis process [9, 
10]. As a result of the loss of adhesion cells mediated by E-cadherin it causes 
cells to separate from the primary tumor, attack the surrounding tissue and 
migrate to distant sites [10]. 
In most cases, in the NPC tissue that has high E-cadherin expression 
and the cells are less invasive and metastatic then it will lead to a good 
prognosis. Reduced expression of E-cadherin often shows a poor clinical 
prognosis in patients with cancer [11]. In many types of cancer including 
NPC, the expression E-cadherin was found to be decreased. Thus it was 
concluded that the decrease in E-cadherin might play a role in tumor 
development and metastasis process [12]. This study aims to determine the 
relationship between E-cadherin expression to the clinical stage of NPC. 
2. MATERIAL AND METHODS 
This study is an analytical study with a cross-sectional study design. This 
research was conducted in the Division of Oncology-Head Neck Surgery 
Department of Otorhinolaryngology-Head-and-Neck Medical Faculty of 
University of Sumatera Utara/H. Adam Malik Medan General Hospital and 
Pathological Anatomy Unit Installation H. Adam Malik Medan General 
Hospital. The study conducted in May-November 2018. 
The population of this study was patients diagnosed with NPC based on 
history taking, physical examination, radiology examination and 
histopathological biopsy results treated at the Division of Oncology-Head 
Neck Surgery of Department of Otorhinolaryngology-Head-and-Neck 
Medical Faculty of University of Sumatera Utara/ H. Adam Malik Medan 
General Hospital. 
The sample of this study was patients diagnosed with NPC based on the 
results of histopathological examination with a sample calculation obtained 
30 samples. The inclusion criteria of this study were patients diagnosed with 
NPC based on histopathological examination results who had never 
received treatment with radiotherapy, chemotherapy or a combination of 
both. Exclusion criteria are missing or damaged paraffin blocks and 
incomplete patient medical records. The research sample was taken by a 
non-probability sampling method by consecutive sampling. 
Preparation after cutting tissue (preparations/slides): preparations are 
heated in high microwave level for 5 minutes. Furthermore, the preparations 
were deparaffinated with xylol I - II - III respectively for 5 minutes, wash in 
running water for 5 minutes and blocking with endogenous peroxidase 
(0.5% H2O2 in methanol) for 30 minutes. Next wash with running water for 
5 minutes. Give tris EDTA pretreatment in a microwave: Cook I: high power 







level for 5 minutes. Cook II: medium power level for 5 minutes. Then it is 
cooled for about 45 minutes. Wash with PBS pH 7.4, then limit tissue with 
Pap-Pen. Blocking non-specific activity with normal serum for 20'. Incubate 
preparations with E-cadherin primary antibodies for one night at 4°C (in the 
refrigerator). Wash with PBS pH7.4. Then incubate with Envision for 30 
minutes. Wash with PBS pH 7.4 - Twin 20 then PBS for 5 minutes each. 
Furthermore, the preparation was given chromogen to be colored with DAB 
(Diamino Benzidine) for approximately 5 minutes. Wash with running 
water. Counterstain with Hematoxylin Lilie Mayers. Wash with running 
water. Saturated Lithium Carbonate (5% in aquadest for 1-2 minutes). Wash 
with running water. Next do dehydration with multilevel alcohol (80% 
alcohol, 96% alcohol, absolute alcohol I and II each for 5 minutes). Clearing 
with xylol I, II, III for 5 minutes each. Cover with Entellan and cover glass. 
Can be read directly. E-cadherin was assessed on the basis of the percentage 
of immunopositive cells as follows: 0.0%; +1, less than 10%; +2, 10-50%; 
and +3, greater than 50%. Staining intensity was evaluated as weak (+1), 
moderate (+2), or strong (+3). When the sum of the proportion score and 
intensity score was more than 4 (range 0-6). The evaluation was carried out 
by 2 pathologists without knowing the patient's clinical data. For the final 
score immunoreactive scores were used, with assessment: no 
overexpression of E-cadherin, immunoreactive score 0-3; E-cadherin 
overexpression, immunoreactive score 4-6 [13]. 
3. RESULT 
The characteristics of the subjects included age, gender, histopathological 
type, primary tumor size, enlargement of the neck lymph nodes and the disease 
stages listed in table 1. 
Table 1. Characteristics of Sample 
Characteristic   n=30 % 
Age   
<20  2  6.7 
20-29  3  10 
30-39  4  13.3 
40-49  6  20 
50-59  10  33.3 
60-69  3  10 
≥70 2  6.7 
Gender   
Male 22 73.3 
Female 8 26.6 
Histopathological Type   
Keratinizing squamous cell carcinoma 0 0 
Non keratinizing squamous cell carcinoma 25 83.3 
Undifferentiated carcinoma 5 16.7 
Primary tumor size   
         T1 5 16.7 
         T2 10 33.3 
         T3 9 30 
         T4 6 20 
Cervical lymph node enlargement   
         N0 2 6.7 
         N1 8 26.7 
         N2 7 23.3 
         N3 13 43.3 
Stage   
         I 0 0 
         II 4 13.3 
         III 11 36.7 
         IV 15 50 
This study was followed by 30 people who met the inclusion criteria. The 
majority of the subjects were male as many as 22 people (73.3%), with the highest age 
in the 50-59 year age group as many as 10 people (33.3%). The average age of the 
study subjects was 46.67 years with the youngest age 18 years and the oldest 73 years. 
From the results of the histopathological examination, it appears that 
the Non-Keratinizing histopathology type is the most common 
histopathological type in this study as many as 25 people (83.3%). The size 
of the primary tumor found in this study was T2 as many as 10 subjects 
(33.3%), at least T1, 5 subjects (16.7%). Most lymph node enlargement was 
N3 as many as 13 subjects (43.3%), at least N0 were 2 subjects (6.7%).                  
The most common disease stage was stage 4, which was 15 patients (50%) 
and no patients with stage 1 were found. 
Table 2. E-Cadherin Expression based on Tumor Size 
Tumor size 
 
E-Cadherin Expression P 
Overexpression No overexpression  
T3 and T4 14 (93.3) 1 (6.7) 1.000 
T1 and T2 15 (100) 0  
From 15 subjects with tumor size T3 and T4, there were 14 people (93.3%) 
who showed overexpression of E-cadherin. Meanwhile, NPC patients with tumor 
size T1 and T2 all showed over-expression of E-cadherin. Using the Fischer’s Exact 
test, it was found that there was no significant association between the size of                    
the nasopharyngeal tumor and E-cadherin expression (p=1.000) 





Overexpression No overexpression 
N2 and N3 19 (95) 1 (5) 1.000 
N0 and N1 10 (100) 0  
From 20 subjects with lymph node involvement N2 and N3, there were 19 
subjects (95%) who showed overexpression. Meanwhile, subjects with lymph 
node involvement N0 and N1 all showed over-expression of E-cadherin.                   
Using the Fischer exact test, it was found that no significant association was 
found between the number of lymph node involvement in the nasopharyngeal 
tumor and the expression of E-cadherin (p=1.000). 
Table 4. E-Cadherin Expression based on Histopathology Type 
Histopathology Type 
 
E-Cadherin Expression P 
Overexpression No overexpression  
Non Keratinizing 24 (96) 1 (4) 1.000 
Undifferentiated Ca 5 (100) 0  
From 25 subjects with Non-Keratinizing NPC, there were 24 people 
(96%) who showed overexpression. Meanwhile, the subjects of the NPC 
with the Undifferentiated Carcinoma type all showed over-expression of                
E-cadherin. Using the Fischer’s Exact test, it was found that no significant 
association was found between the histopathological type of nasopharyngeal 
tumor and E cadherin expression (p=1.000). 




Overexpression No overexpression 
Early 3 (75) 1 (25) 0.133 
Advanced 26 (100) 0  
From 29 samples with E-cadherin overexpression there were 26 subjects 
(100%) with advanced stages. All subjects that did not show overexpression 
amounted to 1 person at an advanced stage. Using the Fischer’s Exact test, it was 
found that no significant association was found between the stage of the 
nasopharyngeal tumor and E-cadherin expression (p=0.133). 
4. DISCUSSION 
The most age group is the age group 50-59 which is as many as 10 
subjects (33.3%) seen in Table 4.1. Similar studies also reported similar 
results, as in Susilo's study (2018) which reported the highest proportion of 
age is in the 41-60 year age group as well as other studies that reported the 
most NPC patients is in the 36-60 year age group [14-16]. 
In this study, the comparison of subjects with male and female gender 
was 2.7:1 (Table 1). Some previous studies that have been conducted both 
in Medan and other countries also show that male NPC sufferers outnumber 
women with an average ratio of 2-3:1 [17-20].  
The incidence of nasopharyngeal cancer in men is 2 to 3 times higher than 
women. This difference between men and women may be caused by differences 
in habits and lifestyle (for example tobacco consumption) or biological 
differences. There is a hypothesis about the role of estrogen in the incidence of 
nasopharyngeal carcinoma, but the relationship between sex hormone exposure 
and the risk of NPC in humans has never been studied epidemiologically [21]. 
The most common histopathological type found in this study was                  
non-keratinizing squamous cell carcinoma as many as 25 subjects (83.3%) 
(Table 1). Similar research conducted at M. Djamil Padang General Hospital 
also showed the highest number of nonkeratinizing squamous cell 
carcinoma types with a percentage of 75% [22]. However, the different 
results reported by extensive studies examining the epidemiology of NPC 
in Indonesia report the most cases in Indonesia are WHO type III 
(undifferentiated carcinoma), with a percentage of 85% [7].  Research in                 
Dr. Cipto Mangunkusumo Hospital also reported the highest percentage of 
histopathological type of NPC was WHO type III (75.4%) [23]. 
In this study, the largest size of the primary tumor found was T2 
(33.3%). The most lymph nodes enlargement found was N3 (43.3%) and the 
most common stage was stage IV (50%). In Indonesia, the highest 







proportion of NPC patients is T4 for tumor size, N3 for neck lymph nodes 
enlargement and advanced clinical stages [7]. At Dr. Cipto Mangunkusumo 
Hospital, the most common patient stages were stadium 4A, 4B and 4. 
From 29 subjects with E-cadherin overexpression there were 15 subjects 
(100%) with tumor size T1 and T2. No significant association was found between 
E-cadherin expression and tumor size (p=1.000) (Table 2). From the results of the 
study, there were 19 subjects (95%) who showed E-cadherin overexpression with 
the lymph node involvement of N2 and N3. No significant association was found 
between E-cadherin expression and lymph node metastasis (p=1.000) (Table 3). Of 
the 25 subjects with Non-Keratinizing NPC there were 24 people (96%) who 
showed E-cadherin overexpression. There was no significant association between 
histopathological type of nasopharyngeal tumor and E cadherin expression 
(p=1.000) (Table 4). Of the 29 subjects with E-cadherin overexpression there were 
26 subjects (100%) with advanced stages. There was no significant association 
between E-cadherin expression and tumor stage (p=0.133) (Table 5). 
No significant association found between E-cadherin expression and 
tumor growth, lymph node metastasis, histopathology type, and tumor stage 
can be explained as follows: 
The process by which tumor cells leave the primary location and reach 
the distant organ to form a new tumor is called metastasis, which is the main 
pathological feature of cancer. During this process, cancer cells originating 
from the epithelium gradually lose their epithelial characteristics and obtain 
a mesenchymal phenotype; this process is called the epithelial-to-
mesenchymal (epithelial-to-mesenchymal/EMT) transition. The molecular 
change in intercellular adhesion is the first step in EMT in cancer cells, and 
a decrease in the regulation of E-cadherin expression is a feature of this 
process. Because E-cadherin mediates cell adhesion through Ca2+ dependent 
homophilic interactions, downregulation of E-cadherin will reduce cell 
adhesion. Previous data showed that E-cadherin was a tumor suppressor. 
However, recent studies have confirmed that E-cadherin suppresses and 
promotes cancer development [11]. 
In NPC with initial metastasis, there will be downregulation of                 
E-cadherin so that the expression of E-cadherin is lower than NPC without 
metastasis. In addition to downregulation, proteolysis process also occurs [24]. 
Down-regulation of E-cadherin will facilitate tumor cells to separate from 
the primary tumor. Although downregulation E-cadherin is needed for an 
invasion, in some cases of malignancy, E-cadherin is maintained. E-cadherin 
consists of many extracellular domains, transmembrane segments, and 
cytoplasmic domains. E-cadherin can undergo proteolysis and release protein 
membrane fragments called ectodomain shedding [25, 26]. 
E-cadherin undergoes division in certain parts. This division produces 
fragments that have different oncogenic properties. Mature E-cadherin 120-
kDa will be divided into an 80-kDa N-terminal extracellular fragment by α-
secretase and 38-kDa C-terminal fragment [11]. This ectodomain fragment 
is called soluble E-cadherin/sE-cad which will be released from the plasma 
membrane and spread diffusely in the extracellular area and a part enter the 
blood vessels as a paracrine/autocrine signaling molecule. While C-terminal 
intracellular fragments (E-cad/CTF1) are retained in the plasma membrane 
until division arises on the intracellular side by γ-secretase [27]. This will 
damage the adherent junction and release the intracellular fragments 33-kDa 
(E-cad/CTF2) into the cytosol and function as intracellular signaling. E-
cadherin fragments are an oncogene. sE-cad reduces the amount of full-
length E-cadherin on the plasma membrane, this will damage the existing 
adherens junction and cause the cell to separate between one cell and 
another cell. This will make it easier for cells to invade [28]. Also, sE-cad 
activates MMP expression to improve the decay of sE-cad (ectodomain 
shedding) and activate EGFR pathway [29]. E-cad/CTF2 activates the 
Wnt/β-catenin pathway signal [2]. 
The proteolysis process of E-cadherin in early NPC metastases was not 
as high as in advanced metastatic NPC so that the E-cadherin fragments 
produced were not as many as E-cadherin fragments produced in proteolysis 
process of E-cadherin in advanced NPC metastatic. Along with the 
development of the tumor, the proteolysis process will increase. This results 
in increased E-cadherin fragments. Both E-cadherin and full-length                
E-cadherin fragments will be smeared on scavenging with E-cadherin 
antibodies so that the expression of E-cadherin in advanced NPC metastatic 
is further higher than that of E-cadherin in early metastatic NPC [24]. 
This is in accordance with previous studies which found that E-cadherin 
expression in the NPC group of advanced metastases was significantly 
higher than the early NPC metastatic group (α=0.05, p <0.05). The mean         
E-cadherin expression in early metastatic NPC (36.4%) was lower than the 
mean expression of E-cadherin in advanced NPC metastases. This means 
that there is a relationship between tumor progression or the degree of 
metastasis and E-cadherin expression in NPC, where the higher the degree 
of NPC metastatic, the higher the expression of E-cadherin in NPC cells [24]. 
There is plenty of evidence that invasive and metastatic cancers 
maintain high levels of E-cadherin expression [11]. About 55% of ductal 
carcinoma of the breast expresses high E-cadherin, and in 45% of other 
patients, E-cadherin expression can also be observed; even in invasive 
lobular carcinoma, E-cadherin expression is present in up to 12% of patients 
[11]. Similarly, high E-cadherin expression is positively correlated with 
invasive growth and infiltration of prostate cancer cells [30]. Besides, other 
studies have found that E-cadherin is highly expressed in glioma cells and 
is positively correlated with poor prognosis in patients with glioblastoma 
[31]. Other researchers observed abnormal E-cadherin expression in human 
ovarian cancer. The researchers examined specimens from 37 ovarian 
cancer cases, which~86.5% had high E-cadherin expression, and found that 
high E-cadherin expression promoted malignant transformation of ovarian 
epithelial cells. Together, these results suggest that high E-cadherin 
expression may not inhibit cancer development; but E-cadherin can also 
encourage metastasis [11]. 
Wilmanns, et al. found that comparison with 6 healthy volunteers 
(3.476 ng/ml), the concentration of sE-cad was significantly higher in 36 
patients with colorectal cancer (5.495 ng/ml). This concentration is strongly 
related to  the tumor size as well as local expansion or spread, as well as the 
highest concentration in patients with carcinoembryonic (CEA)-positive 
liver metastases. Levels of sE-cad were significantly higher in patients with 
stage III-IV colorectal cancer and directly indicated disease progression [11]. 
Other researchers found that serum sE-cad levels were significantly 
increased in 111 breast cancer patients and confirmed that sE-cad levels 
were significantly associated with tumor stage, histopathological grading, 
and lymph node metastasis [32]. 
5. CONCLUSION 
In this study no significant association was found between E-cadherin 
expression and tumor size (p=1.000), lymph node metastasis (p=1.000), 
histopathological type (p=1.000) and tumor stage (p=0.133). For this reason, 
further research is needed to evaluate the association between E-cadherin 
expression to clinical progression of NPC with a larger and more sustainable 
sample, to obtain more reliable data on the effectiveness of E-cadherin as a 
marker of prognosis in nasopharyngeal carcinoma. 
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